Literature DB >> 23579458

Novel chemotherapeutic drugs in sphingolipid cancer research.

Daniel Canals1, Yusuf A Hannun.   

Abstract

Sphingolipid-metabolizing enzymes are becoming targets for chemotherapeutic development with an increasing interest in the recent years. In this chapter we introduce the sphingolipid family of lipids, and the role of individual species in cell homeostasis. We also discuss their roles in several rare diseases and overall, in cancer transformation. We follow the biosynthesis pathway of the sphingolipid tree, focusing on the enzymes in order to understand how using small molecule inhibitors makes it possible to modulate cancer progression. Finally, we describe the most used and historically significant inhibitors employed in cancer research, their relationships to sphingolipid metabolism, and some promising results found in this field.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23579458      PMCID: PMC3998523          DOI: 10.1007/978-3-7091-1368-4_12

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  110 in total

Review 1.  Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Authors:  L G Durrant; P Noble; I Spendlove
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

2.  Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action.

Authors:  J Inokuchi; M Jimbo; K Momosaki; H Shimeno; A Nagamatsu; N S Radin
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

3.  Neutral sphingomyelinase inhibitor C11AG prevents lipopolysaccharide-induced macrophage activation.

Authors:  E Amtmann; W Baader; M Zöller
Journal:  Drugs Exp Clin Res       Date:  2003

Review 4.  Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics.

Authors:  Sheldon Milstien; Sarah Spiegel
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

Review 5.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

6.  Specificity of the dihydroceramide desaturase inhibitor N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11) in primary cultured cerebellar neurons.

Authors:  Gemma Triola; Gemma Fabrias; Mihaela Dragusin; Lars Niederhausen; Roland Broere; Amadeu Llebaria; Gerhild van Echten-Deckert
Journal:  Mol Pharmacol       Date:  2004-09-15       Impact factor: 4.436

Review 7.  Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Authors:  Roland M Schaefer; Anna Tylki-Szymańska; Max J Hilz
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

8.  Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism.

Authors:  Norma Marchesini; Chiara Luberto; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

9.  Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G.

Authors:  Takayuki Noda; Soichi Iwai; Masakazu Hamada; Yusei Fujita; Yoshiaki Yura
Journal:  Apoptosis       Date:  2009-02-06       Impact factor: 4.677

10.  Selectivity and specificity of sphingosine 1-phosphate receptor ligands: "off-targets" or complex pharmacology?

Authors:  Nigel J Pyne; Susan Pyne
Journal:  Front Pharmacol       Date:  2011-05-31       Impact factor: 5.810

View more
  15 in total

Review 1.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

2.  Multiple actions of doxorubicin on the sphingolipid network revealed by flux analysis.

Authors:  Justin M Snider; Magali Trayssac; Christopher J Clarke; Nicholas Schwartz; Ashley J Snider; Lina M Obeid; Chiara Luberto; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2018-12-20       Impact factor: 5.922

Review 3.  Targeting Sphingosine Kinases for the Treatment of Cancer.

Authors:  Clayton S Lewis; Christina Voelkel-Johnson; Charles D Smith
Journal:  Adv Cancer Res       Date:  2018-06-09       Impact factor: 6.242

4.  Ceramide launches an acute anti-adhesion pro-migration cell signaling program in response to chemotherapy.

Authors:  Daniel Canals; Silvia Salamone; Bruno Jaime Santacreu; Erika Nemeth; Daniel Aguilar; María José Hernandez-Corbacho; Mohamad Adada; Daniela I Staquicini; Wadih Arap; Renata Pasqualini; John Haley; Lina M Obeid; Yusuf A Hannun
Journal:  FASEB J       Date:  2020-04-20       Impact factor: 5.191

5.  Probing compartment-specific sphingolipids with targeted bacterial sphingomyelinases and ceramidases.

Authors:  Wataru Sakamoto; Daniel Canals; Silvia Salamone; Janet Allopenna; Christopher J Clarke; Justin Snider; Lina M Obeid; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2019-06-26       Impact factor: 5.922

Review 6.  Sphingolipids and Lymphomas: A Double-Edged Sword.

Authors:  Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

7.  Surface cholesterol-enriched domains specifically promote invasion of breast cancer cell lines by controlling invadopodia and extracellular matrix degradation.

Authors:  Mauriane Maja; Danahe Mohammed; Andra C Dumitru; Sandrine Verstraeten; Maxime Lingurski; Marie-Paule Mingeot-Leclercq; David Alsteens; Donatienne Tyteca
Journal:  Cell Mol Life Sci       Date:  2022-07-12       Impact factor: 9.207

8.  Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Authors:  Samy A F Morad; Su-Fern Tan; David J Feith; Mark Kester; David F Claxton; Thomas P Loughran; Brian M Barth; Todd E Fox; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-03-10

Review 9.  Sphingolipids in colon cancer.

Authors:  Mónica García-Barros; Nicolas Coant; Jean-Philip Truman; Ashley J Snider; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-09-21

Review 10.  Neutral ceramidase: Advances in mechanisms, cell regulation, and roles in cancer.

Authors:  Nicolas Coant; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.